Industry research
Pharmaceuticals & Biotechnology market research
Evaluate pharmaceutical and biotechnology opportunities across disease, treatment, development stage, and commercial access. Pipeline counts need a defined asset, indication, and trial status.
Market definition
Set the boundary before comparing.
A drug, molecule, indication, and patient population are not interchangeable market units. Tie the estimate to a treatment setting and development stage.
01Therapy area
Diagnosed patients, treated patients, or spending
Set disease definition, line of therapy, eligible population, and geography.
02Drug modality
Assets, courses, doses, or product sales
Distinguish small molecules, biologics, vaccines, cell and gene therapies, and biosimilars.
03Development pipeline
Assets by phase, indication, or probability
Count unique assets and identify trial phase, status date, sponsor, and indication.
04Manufacturing and services
Capacity, batches, contracts, or revenue
Separate API, finished dose, CDMO, and internal production activity.
Decision context
What shapes the opportunity?
Use these lenses to build a market view around the decision, customer, and time horizon that matter to you.
- 01
Clinical evidence and attrition
Compare trial design, endpoint, safety profile, comparator, and transition rates by phase.
- 02
Access and pricing
Review approval, reimbursement, launch sequencing, price controls, and patient access by country.
- 03
Lifecycle and competition
Track exclusivity, biosimilar or generic entry, new indications, and competing mechanisms of action.
Buyer questions
Questions worth resolving.
Use these checks to test whether a report answers your decision or needs a narrower research brief.
- 01
How is the patient population defined?
Start with prevalence or incidence, then apply diagnosis, eligibility, treatment line, access, and adherence.
- 02
Which pipeline assets are comparable?
Deduplicate products across indications and separate active trials from paused, withdrawn, or historical programs.
- 03
What value can be commercialized?
Distinguish epidemiological need from reimbursed treatment, addressable sales, and manufacturer net revenue.
Definitions and evidence
Check what the measures represent.
Drug discovery, preclinical work, clinical research, regulatory review, and post-market monitoring describe different stages. Count a development programme by its indication and stage before treating it as a marketed treatment or commercial opportunity.
- FDA: the drug development process
Sets out the US development, review, and post-market stages without forecasting commercial success.
A pipeline count does not establish approval probability, eligible treated patients, net price, reimbursement, or achievable sales. The FDA process is a US reference; commercial assumptions need separate evidence for each market and indication.
Reference sources checked .
Related analysis
Evidence for your next decision.
Explore the commercial questions behind this research coverage.
- Pharma Launch Economics: Patient Access, Persistence and Net Receipts
Assess an approved product launch through label scope, access, supply, treatment starts, persistence and product-level net receipts.
- Pharma Opportunity Assessment: From Pipeline Assets to Treatable Patients
Assess an asset at indication level using development status, clinical eligibility, diagnosis, access and treatment capacity.
Your next question
Define the indication and treatment path.
Tell us what you need to compare, where, and for whom. We’ll confirm relevant report coverage or shape a custom study.